Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 13/20 | 0.79 |
| ▸ | TOP1 | P11387 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | CRHBP | P24387 | 1/20 | 0.74 |
| ▸ | CASP7 | P55210 | 1/20 | 0.74 |
| ▸ | CASP6 | P55212 | 1/20 | 0.74 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | GALK1 | P51570 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385323 | 0.89 | NQO1 (1.00) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL4388805 | 0.88 | VKORC1 (0.76) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL16709246 | 0.87 | NQO1 (0.79) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL7357206 | 0.86 | NQO1 (0.76) | NQO1TOP1CYP2C9KDM4EMEN1 | |
| SCHEMBL4390609 | 0.85 | NQO1 (1.00) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL7899682 | 0.85 | NQO1 (0.86) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL14172083 | 0.85 | NQO1 (1.00) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL7896856 | 0.84 | NQO1 (1.00) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL28169141 | 0.84 | NQO1 (0.76) | NQO1TOP1CYP2C9CRHBPCASP7 | |
| SCHEMBL7898320 | 0.82 | NQO1 (0.86) | NQO1TOP1CYP2C9CRHBPCASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133493-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER | 2015-05-14 | — | — | US | disclosed |
| US-20150133493-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER | 2015-05-14 | — | — | US | disclosed |
| US-20110306605-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306605-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2010075280-A2 | COUMARIN-BASED COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133493-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | BACE1, PSEN1, APP | NQO1 174/4885TOP1 431/4885CYP2C9 877/4885 |
| US-20110306605-A1 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER | BACE1, PSEN1, APP | NQO1 174/4885TOP1 431/4885CYP2C9 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.